Medication for quitting smoking

Photo of a packet of pills
PantherMedia / Albert Lozano

Taking medication to help you quit smoking can somewhat increase the chances of success. The possible side effects include temporary sleep problems and nausea.

Two medications to help people quit smoking tobacco have been approved for use in Germany: bupropion (trade name Zyban) and varenicline (EU: Champix, U.S.: Chantix). They are prescription-only, so they have to be prescribed by a doctor. Statutory health insurers don’t cover the costs of these medications in Germany.

There are a lot of studies on the effectiveness of bupropion and varenicline. In the studies, the researchers looked at whether the participants still smoked, or had started smoking again, after 6 to 12 months.

Bupropion (Zyban)

The drug bupropion was originally developed for the treatment of depression. Because it was also found to help relieve nicotine withdrawal symptoms, it was approved as an aid to quit smoking, under the trade name “Zyban.” It is taken once or twice a day in the form of a tablet, and doesn’t have to be taken with meals. One tablet contains 150 mg of bupropion.

You start the treatment before trying to quit smoking: The first tablet is taken 1 to 2 weeks before the day on which you want to quit. You then carry on taking the tablets for seven weeks.

Research results

Researchers from the and the U.S. () systematically analyzed studies on this drug. They found that bupropion helps about 6 out of 100 people to successfully quit smoking.

Illustration: How effectively bupropion helps people to quit smoking – as described in the information

One large study also looked into whether taking 300 mg bupropion per day is more effective than taking 150 mg bupropion per day. The two doses were found to be equally effective.

The possible side effects of bupropion include sleep problems, mouth dryness and nausea. About 12 out of 100 participants experienced sleep problems. Mouth dryness and nausea were less common. There is also a very small risk of serious side effects such as seizures. These side effects occurred in considerably less than 1 out of 100 participants.

Bupropion can somewhat limit potential weight gain caused by quitting smoking – but only during the treatment. People who took it for 6 to 12 months gained about one kilogram less than those who took a placebo (fake drug). Several months later there was no longer any difference.

The researchers also analyzed studies on other antidepressants and the herbal medicine St. John’s wort. But these medications weren’t found to help people quit smoking.

Varenicline (EU: Champix, U.S.: Chantix)

Another medication that’s available for people who would like to quit smoking is called varenicline (trade name: Champix in the EU, Chantix in the U.S.). It has two effects: On the one hand it relieves nicotine withdrawal symptoms; on the other, it makes smoking less pleasurable.

Treatment with varenicline is also started before people try to quit smoking. The dose is then gradually increased. You take

  • one 0.5 mg tablet per day on the first 3 days of treatment,
  • two 0.5 mg tablets per day on days 4 to 7 of treatment, and
  • two 1 mg tablets per day from the second week of treatment onwards. People also stop smoking in the second week of treatment.

Varenicline tablets are taken in the morning and evening with a glass of water, not necessarily with meals. The treatment lasts twelve weeks in total.

It can make you feel sleepy, affecting your ability to drive. So it’s a good idea to stop driving or operating machinery until you know how you react to the medication.

Research results

Varenicline is currently thought to be the most effective medication for quitting smoking. Studies show that it helps about 12 out of 100 people to stop smoking tobacco.

Illustration: How effectively varenicline helps people to quit smoking – as described in the information

Varenicline caused nausea in about 20 out of 100 people in the studies. But the nausea was often only mild and went away again during the course of the treatment. About 5 out of 100 people had sleep problems and/or strange dreams.

The aim of gradually increasing the dose at the beginning of the treatment is to prevent side effects like nausea. People who still don’t tolerate varenicline well can reduce the dose by a half (two 0.5 mg tablets per day). If someone has advanced kidney failure, they shouldn’t take more than 1 mg per day.

Varenicline doesn’t appear to have an effect on people’s weight.

Is varenicline safe?

For a long time it was suspected that varenicline increases the risk of cardiovascular (heart and blood vessel) disease, as well as emotional problems such as mood swings and irritability. But extensive analyses of studies involving more than 10,000 participants didn’t confirm these suspicions.

The researchers from the analyzed and summarized data on all of the severe side effects of varenicline. They found that less than 1 out of 100 people experienced severe side effects. But a small risk cannot be ruled out. People who have mental health issues or a heart problem can look out for changes in their mood, or for symptoms such as chest pain, and seek medical advice if necessary.

Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016; (5): CD006103.

Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014; (1): CD000031.

Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EP. Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force. September 2015. (AHRQ Evidence Syntheses; Volume 134).

Sterling LH, Windle SB, Filion KB, Touma L, Eisenberg MJ. Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2016; 5(2): e002849.

Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015; 350: h1109.

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on August 24, 2017
Next planned update: 2021


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.